

Thu 1 Dec
10:30 - 11:00 | **Welcome - Opening Ceremony**
Plenary

Chairs : A. Santos (London, United Kingdom), R. van Ree (Amsterdam, Netherlands), I. Carrapatoso (Coimbra, Portugal), B. Eberlein (München, Germany)

Thu 1 Dec
11:00 - 12:15 | **Mechanisms & Methods**
Plenary

Chairs : A. Nopp (Stockholm, Sweden)

To describe and discuss new methods in cellular assays for IgE-mediated allergies

2.1 To describe and discuss new methodological approaches with basophils for detection of clinically relevant allergic sensitization

2.3 To describe and discuss a novel functional mast cell assay for IgE-mediated allergies

11:00 **CytoBas: Flow cytometric staining of basophils with recombinant allergen tetramers**
M. van Zelm (Clayton, Australia)

11:25 **A novel functional mast cell assay for the detection of allergies**
A. Eggel (Bern, Switzerland)

11:50 **Oral Abstracts Discussion**

Thu 1 Dec
12:30 - 13:45 | **BAT/MAT in immediate drug hypersensitivity**
Plenary

Chairs : C. Mayorga (Málaga, Spain)

To describe and discuss IgE-independent mechanisms in immediate drug hypersensitivity and to describe drug allergens that recently have become more relevant in the Corona pandemic

3.1 To understand different mast cell receptors in immediate drug hypersensitivity

3.3 To understand the relevance of BAT for allergies to COVID-19 vaccines

12:30 **Mast cell receptors beyond IgE and its relevance in immediate drug hypersensitivity**
V. Sabato (Antwerp, Belgium)

12:55 **Basophil activation tests and allergy to COVID-19 vaccines**
B. Eberlein (München, Germany)

13:20 **Oral Abstracts Discussion**

Thu 1 Dec

15:30 - 16:45

BAT in food allergy

Plenary

Chairs : A. Santos (London, United Kingdom)

To describe and discuss new insights of BAT in food allergy

4.1 To describe and discuss new aspects of BAT in peanut and tree nut allergy

4.3 To describe and discuss new aspects of BAT in allergy to LTP

15:30

Basophil activation test in peanut and tree nut allergy

T. Eiwegger (St. Poelten, Austria)

15:55

BAT as a diagnostic tool in allergy to lipid transfer proteins (LTP)

C. Mayorga (Málaga, Spain)

16:20

Oral Abstracts Discussion

Thu 1 Dec

17:00 - 18:15

BAT in immunotherapy

Plenary

To understand the application of BAT as biomarker during immunotherapy

5.1 To understand and discuss the application of BAT during bee venom immunotherapy

5.3 To understand and discuss the application of BAT during grass pollen immunotherapy

17:00

Biomarkers of adverse events during bee venom immunotherapy

P. Korosec (Golnik, Slovenia)

17:25

Basophil sensitivity during immunotherapy in grass pollen-allergic patients

17:50

Oral Abstracts Discussion

Fri 2 Dec
09:00 - 10:30 | **Risk factors & Prevention of Food Allergy**
Plenary

Chairs : G. du Toit (London, United Kingdom)

- 1.1 To explain the effects of diet and microbiome on the immune system and rationale for their use in food allergy prevention
- 1.3 To describe the recent evidence and ongoing studies on the effect of interventions on the skin barrier in the development of food allergy
- 1.5 To discuss the practical aspects of introducing allergenic foods in the infants' diet and their implication for public health

09:00 **Immunonutrition and microbiome for prevention**
L. O'Mahony (Cork, Ireland)

09:25 **Targeting the skin barrier to prevent food allergy**
H. Brough (London, United Kingdom)

09:50 **Implementing early introduction of allergenic foods**
G. Roberts (Southampton, United Kingdom)

10:15 **Oral Abstracts Discussion**

Fri 2 Dec
10:45 - 12:15 | **Best Practice in Food Allergy Diagnosis**
Plenary

Chairs : I. Skypala (London, United Kingdom)

- 2.1 To enumerate the key messages about food allergy diagnosis reported in the MAUG 2.0
- 2.3 To describe the main findings of the systematic review of the literature that forms the basis for the new EAACI Food Allergy Guidelines
- 2.5 To discuss novel approaches for diagnostic tests for food allergy that are making the transition to clinical practice and their added value to existing tests

10:45 **Highlights of the molecular allergology users' guide**
K. Hoffmann-Sommergruber (Wien, Austria)

11:10 **EAACI guidelines on food allergy diagnosis**
C. Riggioni-Viquez (Singapore, Singapore)

11:35 **Emerging diagnostic tests for food allergy**
A. Santos (London, United Kingdom)

12:00 **Oral Abstracts Discussion**

Fri 2 Dec
14:00 - 15:30

Allergens and Immune Mechanisms of Food Allergy

Plenary

Chairs : E. Untersmayr (Wien, Austria)

- 3.1 To describe the immune mechanisms underlying FPIES and other non-IgE mediated food allergy clinical entities
- 3.3 To enunciate measures of allergenicity of food proteins and their use in the evaluation of probability of inducing clinical reactions in allergic individuals
- 3.5 To explain the changes in the allergic immune response during desensitisation and natural acquisition of tolerance

14:00 Mechanisms of non IgE mediated food allergy

C. Berin (New York, United States of America)

14:25 Allergenicity and risk assessment

R. van Ree (Amsterdam, Netherlands)

14:50 Immune responses in desensitization and tolerance

M. Kulis (Chapel Hill, United States of America)

15:15 Oral Abstracts Discussion

Fri 2 Dec
15:45 - 17:00

What's new in Anaphylaxis

Plenary

Chairs : G. Konstantinou (Thessaloniki, Greece)

- 4.1 To describe the differences in clinical presentation and management of anaphylaxis induced by different agents using examples from the european anaphylaxis registry
- 4.3 To explain the physiologic changes during an episode of anaphylaxis based on evidence from food challenges
- 4.5 To discuss the differences between adrenaline auto-injectors, the evidence supporting its prescription and availability around the world

15:45 Anaphylaxis to drugs, insects and foods: any differences?

M. Worm (Berlin, Germany)

16:10 Physiopathology of anaphylaxis

P. Turner (London, United Kingdom)

16:35 Adrenaline auto-injectors

L. Tanno (Montpellier, France)

Oral Abstracts Discussion

Sat 3 Dec

09:00 - 10:30

Allergen-Specific Immunotherapy for Food Allergy

Plenary

Chairs : A. Alvarez-Perea (Madrid, Spain)

- 1.1 To explain the mechanism, efficacy and safety of nanoparticles as a vehicle of food allergen immunotherapy
- 1.3 To articulate the mechanisms and possible indications of adjuvants of food allergen immunotherapy
- 1.5 To outline the practicalities and challenges of starting and maintaining a food allergen immunotherapy service

09:00 **Nanoparticles approaches in food allergy immunotherapy**

09:25 **Adjuvants in immunotherapy**

09:50 **Implementing immunotherapy in clinics**
P. Rodríguez del Río (Madrid, Spain)

10:15 **Oral Abstracts Discussion**

Sat 3 Dec
10:45 - 12:15

How Allergen Thresholds can inform Clinical Management of the food Allergic Patient

Plenary

Chairs : A. Santos (London, United Kingdom)

- 2.1 To elaborate on the use of allergen threshold to inform clinical decision making and recommendations to patients
- 2.2 To explain the implications of allergen threshold for the practical daily management of food allergies
- 2.3 To identify the issues that allergen thresholds can help address in the food industry
- 2.4 To report the limitations of methods used for detection of allergen in foods and utility of allergen thresholds
- 2.5 To recognise the methods used to calculate allergen thresholds at the population and the individual level

10:45 **The clinical' perspective**
M. Fernández-Rivas (Madrid, Spain)

10:55 **The patient' perspective**

11:05 **Food industry perspective**
R. Crevel (Manchester, United Kingdom)

11:15 **The science perspective**
C. Mills (Manchester and Guildford, United Kingdom)

11:25 **The data scientist perspective**

11:35 **Pannel discussion and Q&A**
B. Vlieg (Amsterdam, Netherlands), R. Knibb (Birmingham, United Kingdom)

Sat 3 Dec

14:00 - 15:30

Biologics and new therapeutic approaches for food allergy

Plenary

Chairs : T. Eiwegger (St. Poelten, Austria)

3.1 To describe current evidence about the efficacy and safety of anti-IgE antibodies in the treatment of food allergy

3.3 To explain the mechanism and clinical evidence to support the use of small molecules in the treatment of food allergy

3.5 To outline the generation of allergen-specific monoclonal antibodies from human samples and its potential application in therapy of food allergy

14:00

Is there a role for anti-IgE biologics as monotherapy for food allergy?

S. Chinthrajah (Stanford, United States of America)

14:25

Small molecules for inhibiting IgE synthesis and function

A. Eggel (Bern, Switzerland)

14:50

Allergen-specific monoclonal antibody cocktails

D. Croote (South San Francisco, United States of America)

15:15

Oral Abstracts Discussion

Sat 3 Dec

15:45 - 16:00

Closing Addresses

Plenary

15:45

Closure

A. Santos (London, United Kingdom), R. van Ree (Amsterdam, Netherlands), I. Carrapatoso (Coimbra, Portugal), B. Eberlein (München, Germany)